Period Tracker App Clue Gets $7M To Build A Platform For Female Health
Context & Ripple Effects
Clue's $7M raise marks the moment a Berlin period-tracking app started positioning itself as more than a calendar: the stated goal is a platform for female health built on the cycle data its users generate daily. That framing set up everything that followed in this coverage arc, from Clue's $20M Series B led by Nokia Growth Partners a year later to its eventual push into regulated products.
The competitive frame matters too: Swedish rival Natural Cycles took a narrower but clinically bolder route, raising $30M for its FDA-cleared digital contraception app — a bet that cycle data plus statistical prediction could substitute for hardware contraception. Clue later validated the same thesis when it won FDA clearance to debut its own digital contraceptive for its ~13M users.
First-order effects
- Clue now has capital to hire and build beyond the tracking app itself, shifting it from a single-purpose utility toward a data platform competing for the same users Natural Cycles targets.
Second-order effects
- Rivals are pushed to differentiate on regulatory clearance rather than features: Natural Cycles' digital-contraction funding rounds show investors rewarding clinical validation over raw user counts, pressuring Clue to pursue FDA pathways of its own — which it ultimately did.
Third-order effects
- If the pattern holds, femtech consolidates around two defensible moats — scale of longitudinal health data (Clue's path) and cleared medical claims (Natural Cycles') — leaving pure tracker apps without either as acquisition targets rather than standalone businesses.
The trend: Cycle-tracking apps are evolving into regulated medical platforms, with venture funding increasingly flowing to apps that convert menstrual data into FDA-cleared health products.